Abstract:Background & Aims Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Endoscopic eradication therapy (EET) can be effective in eradicating BE and related neoplasia and has greater risk of harms and resource use than surveillance endoscopy. This clinical practice guideline aims to inform clinicians and patients by providing evidence-based practice recommendations for the use of EET in BE and related neoplasia. Methods The Grading of Recommendations Assessment, Development and Evaluation framework was used to assess evidence and make recommendations. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients, conducted an evidence review, and used the Evidence-to-Decision Framework to develop recommendations regarding the use of EET in patients with BE under the following scenarios: presence of (1) high-grade dysplasia, (2) low-grade dysplasia, (3) no dysplasia, and (4) choice of stepwise endoscopic mucosal resection (EMR) or focal EMR plus ablation, and (5) endoscopic submucosal dissection vs EMR. Clinical recommendations were based on the balance between desirable and undesirable effects, patient values, costs, and health equity considerations. Results The panel agreed on 5 recommendations for the use of EET in BE and related neoplasia. Based on the available evidence, the panel made a strong recommendation in favor of EET in patients with BE high-grade dysplasia and conditional recommendation against EET in BE without dysplasia. The panel made a conditional recommendation in favor of EET in BE low-grade dysplasia; patients with BE low-grade dysplasia who place a higher value on the potential harms and lower value on the benefits (which are uncertain) regarding reduction of esophageal cancer mortality could reasonably select surveillance endoscopy. In patients with visible lesions, a conditional recommendation was made in favor of focal EMR plus ablation over stepwise EMR. In patients with visible neoplastic lesions undergoing resection, the use of either endoscopic mucosal resection or endoscopic submucosal dissection was suggested based on lesion characteristics. Conclusions This document provides a comprehensive outline of the indications for EET in the management of BE and related neoplasia. Guidance is also provided regarding the considerations surrounding implementation of EET. Providers should engage in shared decision making based on patient preferences. Limitations and gaps in the evidence are highlighted to guide future research opportunities.

S702 Risk-Aligned Management Guided by the Tissue Systems Pathology Test Can Improve Health Outcomes in Barrett's Esophagus and Reduce Healthcare-Associated Costs

Enhancing the Positive Predictive Value of EGD for Diagnosis of Barrett's Esophagus Through EsoGuard® Triage

S581 A Community-Based Study to Assess a Prognostic Assay's Impact on Gastroenterologists' Barrett's Esophagus Patient Surveillance and Treatment Recommendations

A Systematic Review and Meta-Analysis of the Treatment for Barrett’s Esophagus

Cost‐effective identification of Barrett's esophagus in the community: A first step towards screening

Predicting the Risk of Progression from Barrett's Esophagus to Esophageal Adenocarcinoma with a Mass-Spectrometry-Based Proteomic Panel

SAGES TAVAC safety and efficacy analysis WATS3D (CDx Diagnostics, Suffern, NY)

Predicting Regression of Barrett's Esophagus—Can All the King's Men Put It Together Again?

Comparative Cost Effectiveness of Reflux-Based and Reflux-Independent Strategies for Barrett's Esophagus Screening

AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett's Esophagus and Related Neoplasia

Adjunctive Use of Wide-Area Transepithelial Sampling-3D in Patients With Symptomatic Gastroesophageal Reflux Increases Detection of Barrett's Esophagus and Dysplasia

547. DISEASE SPECIFIC MORTALITY OF EARLY-STAGE ESOPHAGEAL NEOPLASIA IN BARRETT’S ESOPHAGUS TREATED WITH ENDOSCOPIC THERAPY

S681 Identifying Predictors of On-Time Surveillance in Patients With Barrett's Esophagus Post-Endoscopic Eradication Therapy

Association of B Cells in Tumor Microenvironment (TME) with Clinical Benefit to Programmed Cell Death Protein-1 (PD-1) Blockade Therapy in Esophageal Squamous Cell Carcinoma (ESCC).

Use of the EsoGuard® Molecular Biomarker Test in Non-Endoscopic Detection of Barrett's Esophagus among High-Risk Individuals in a Screening Population

Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline

Quality of life, clinical outcomes and cost utilization of endoscopic therapy in patients with Barrett's esophagus and early esophageal cancer-an 8-year Canadian experience

Real-time diagnosis of Barrett's esophagus: a prospective, multicenter study comparing confocal laser endomicroscopy with conventional histology for the identification of intestinal metaplasia in new users

Multicenter, Prospective Trial Of Non-Endoscopic Biomarker-Driven Detection Of Barrett'S Esophagus And Esophageal Adenocarcinoma

ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus

Algorithm Training and Testing for a Non-Endoscopic Barrett's Esophagus Detection Test in Prospective Multicenter Cohorts